#1 Clinical Trials Search in Europe

Other Hormone Antagonists And Related Agents

This article discusses recent clinical trials investigating the use of Other Hormone Antagonists and Related Agents, specifically apalutamide, in the treatment of various stages of prostate cancer. These studies aim to evaluate the efficacy and safety of apalutamide in combination with other therapies for patients with high-risk localized, locally advanced, or metastatic castration-sensitive prostate cancer. The trials explore different treatment approaches, including the use of apalutamide before and after surgical procedures, in combination with radiation therapy, and with intermittent androgen deprivation therapy.

Table of Contents

Introduction

Other hormone antagonists and related agents are a class of medications used in the treatment of prostate cancer. These drugs work by blocking the effects of male hormones (androgens) on cancer cells, helping to slow or stop the growth of prostate tumors. In this article, we’ll explore what these medications are, how they work, and their potential benefits for patients with prostate cancer.

What Are Other Hormone Antagonists?

Other hormone antagonists and related agents are a group of medications that belong to the broader category of hormone therapy for prostate cancer. These drugs are specifically designed to target and block the effects of androgens, such as testosterone, which can stimulate the growth of prostate cancer cells. One example of a medication in this class is apalutamide, which is being studied extensively in clinical trials for various stages of prostate cancer[1][2][3].

How Do They Work?

These medications work by binding to the androgen receptors on prostate cancer cells, preventing the natural androgens from attaching and stimulating cancer growth. By doing so, they help to slow down or stop the progression of prostate cancer. This approach is often referred to as androgen deprivation therapy (ADT) when combined with other treatments that lower testosterone levels in the body[1].

What Conditions Do They Treat?

Other hormone antagonists and related agents are primarily used to treat various stages of prostate cancer, including:

  • Metastatic Castration-Sensitive Prostate Cancer (mCSPC): This is prostate cancer that has spread beyond the prostate gland but still responds to treatments that lower testosterone levels[1].
  • High-risk Localized or Locally Advanced Prostate Cancer: This refers to prostate cancer that is confined to the prostate or nearby tissues but has a high risk of spreading[2][3].

How Are They Administered?

These medications are typically administered in combination with other treatments. For example:

  • They may be given along with androgen deprivation therapy (ADT), which involves medications or surgical procedures to lower testosterone levels in the body[1].
  • They can be used before and after radical prostatectomy (surgical removal of the prostate) with pelvic lymph node dissection (pLND)[3].
  • They may be combined with radiation therapy for certain types of prostate cancer[2].

The specific medication in this class, such as apalutamide, is usually taken orally in the form of tablets[1][2][3].

Effectiveness

Clinical trials are ongoing to determine the effectiveness of these medications in various scenarios. Some of the outcomes being studied include:

  • Metastasis-Free Survival (MFS): This measures how long patients live without the cancer spreading to other parts of the body[1][2][3].
  • Pathological Complete Response (pCR) Rate: This assesses how well the treatment eliminates all detectable cancer cells[3].
  • Radiographic Progression-Free Survival (rPFS): This measures how long patients live without the cancer progressing, as seen on imaging scans[1].

Potential Side Effects

While these medications can be effective in treating prostate cancer, they may also cause side effects. Some potential side effects that patients should be aware of include:

  • Hot flashes: These medications can affect hormone levels, which may lead to sudden feelings of warmth[1].
  • Fatigue: Some patients may experience increased tiredness or weakness.
  • Changes in liver function: Regular monitoring of liver enzymes may be necessary[1][2][3].
  • Cardiovascular effects: There may be an increased risk of heart-related issues in some patients[2][3].

It’s important for patients to discuss potential side effects with their healthcare provider before starting treatment.

Ongoing Research

Several clinical trials are currently underway to further investigate the use of other hormone antagonists and related agents in prostate cancer treatment. These studies aim to determine:

  • The effectiveness of these medications in different stages of prostate cancer[1][2][3].
  • The optimal duration and timing of treatment[1].
  • The benefits of combining these medications with other treatments like radiation therapy or surgery[2][3].
  • The long-term effects and safety profile of these medications[1][2][3].

As research continues, our understanding of how to best use these medications in prostate cancer treatment will likely improve, potentially leading to better outcomes for patients.

Aspect Details
Drug Studied Other Hormone Antagonists and Related Agents (specifically apalutamide)
Cancer Types High-risk localized, locally advanced, and metastatic castration-sensitive prostate cancer
Treatment Combinations Apalutamide with ADT, radiation therapy, and/or surgical procedures
Primary Objectives Improve metastasis-free survival, pathological complete response rates, and reduce side effects
Key Eligibility Criteria Adult men with specific prostate cancer stages, adequate organ function, no contraindicated medical conditions
Evaluation Methods Conventional imaging, PSMA PET imaging, pathology reviews, and clinical assessments
Safety Considerations Monitoring for side effects, organ function, and potential drug interactions

FAQ

  • What is apalutamide and how does it work in prostate cancer treatment? Apalutamide is a type of hormone antagonist used in prostate cancer treatment. It works by blocking the effects of androgens (male hormones) on prostate cancer cells, which can help slow down or stop the growth of cancer cells.
  • What types of prostate cancer are being studied in these clinical trials? These clinical trials are studying the use of apalutamide in various stages of prostate cancer, including high-risk localized prostate cancer, locally advanced prostate cancer, and metastatic castration-sensitive prostate cancer (mCSPC).
  • How is apalutamide being combined with other treatments in these studies? Apalutamide is being studied in combination with various treatments, including androgen deprivation therapy (ADT), radiation therapy, and surgical procedures like radical prostatectomy. Some trials are also exploring intermittent use of ADT with apalutamide.
  • What are the main goals of these clinical trials? The main goals of these trials include evaluating the effectiveness of apalutamide in improving outcomes such as metastasis-free survival, pathological complete response rates, and reducing side effects like hot flashes. They also aim to assess the safety and tolerability of apalutamide in different treatment regimens.
  • Who is eligible to participate in these clinical trials? Eligibility varies between trials but generally includes adult men with specific stages of prostate cancer, adequate organ function, and no history of certain medical conditions that could interfere with the study treatment. Specific criteria such as Gleason scores, PSA levels, and previous treatments are also considered.

Ongoing Clinical Trials on Other Hormone Antagonists And Related Agents

  • Study on Apalutamide and Drug Combination for Patients with Metastatic Castration-Sensitive Prostate Cancer

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Poland

  • Study of Apalutamide and Androgen Deprivation Therapy for Patients with High-Risk Prostate Cancer

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Germany Italy The Netherlands Poland +1

  • Study on the Effectiveness and Safety of Apalutamide and GnRH Agonist in Patients with High-Risk Prostate Cancer Undergoing Radiation Therapy

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia France Germany Italy Poland +3

Glossary

  • Apalutamide: A type of hormone antagonist used in prostate cancer treatment that blocks the effects of androgens on cancer cells.
  • Androgen Deprivation Therapy (ADT): A treatment that reduces levels of male hormones in the body to slow the growth of prostate cancer.
  • Metastatic Castration-Sensitive Prostate Cancer (mCSPC): Prostate cancer that has spread beyond the prostate gland but still responds to treatments that lower testosterone levels.
  • Gleason Score: A grading system used to determine the aggressiveness of prostate cancer based on how the cancer cells look under a microscope.
  • PSA (Prostate-Specific Antigen): A protein produced by the prostate gland; elevated levels may indicate prostate cancer or other prostate conditions.
  • Radical Prostatectomy: A surgical procedure to remove the entire prostate gland and surrounding tissues.
  • Metastasis-Free Survival (MFS): The length of time during and after treatment that a patient lives without cancer spreading to other parts of the body.
  • ECOG Performance Status: A scale used to assess how a patient's disease is progressing and how it affects daily living abilities.
  • Pathological Complete Response (pCR): The absence of all detectable cancer in tissue samples removed during surgery after treatment.
  • PSMA PET Imaging: A specialized imaging technique used to detect prostate cancer cells throughout the body.

References

  1. http://clinicaltrials.eu/trial/study-on-apalutamide-and-drug-combination-for-patients-with-metastatic-castration-sensitive-prostate-cancer/
  2. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-apalutamide-and-gnrh-agonist-in-patients-with-high-risk-prostate-cancer-undergoing-radiation-therapy/
  3. http://clinicaltrials.eu/trial/study-of-apalutamide-and-androgen-deprivation-therapy-for-patients-with-high-risk-prostate-cancer/